Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theravance Biopharma

10.95
-0.3000-2.67%
Post-market: 10.950.00000.00%18:49 EDT
Volume:246.15K
Turnover:2.70M
Market Cap:547.51M
PE:-9.24
High:11.27
Open:11.27
Low:10.90
Close:11.25
Loading ...

BRIEF-Theravance Biopharma - Theravance And Mylan Enter Settlement Agreement With Eugia - SEC Filing

Reuters
·
06 Jun

Theravance Biopharma Inc - Settlement Resolves Patent Litigation Against Eugia - SEC Filing

THOMSON REUTERS
·
06 Jun

Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Reuters
·
06 Jun

Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty

TIPRANKS
·
05 Jun

Rhonda Farnum, SVP of Comm & Medical Affairs, Reports Disposal of Common Shares in Theravance Biopharma Inc

Reuters
·
05 Jun

Theravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating

TIPRANKS
·
03 Jun

Theravance Biopharma Sells Trelegy Royalty Interest to GSK

TIPRANKS
·
02 Jun

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

THOMSON REUTERS
·
02 Jun

Theravance Biopharma Inc - Financial Guidance for 2025 Remains Unchanged

THOMSON REUTERS
·
02 Jun

Theravance Biopharma Inc - Retains Rights to up to $150 Mln in Milestones From Royalty Pharma on Trelegy Ellipta Net Sales in 2025 & 2026

THOMSON REUTERS
·
02 Jun

Press Release: Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Dow Jones
·
02 Jun

Theravance Biopharma Holds 2025 Annual General Meeting

TIPRANKS
·
21 May

Theravance Biopharma Inc. Conducted Annual Shareholders Meeting

Reuters
·
21 May

Theravance Biopharma Inc. to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Reuters
·
13 May

Theravance Biopharma Reports Strong Growth and Optimism

TIPRANKS
·
10 May

Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Theravance Biopharma Q1 EPS $(0.27) Misses $(0.23) Estimate, Sales $15.39M Miss $15.50M Estimate

Benzinga
·
09 May

Theravance Biopharma Reports 6% Increase in YUPELRI Sales, $13.6 Million Net Loss in Q1 2025

Reuters
·
09 May

BRIEF-Theravance Biopharma Q1 Operating Income USD -14.434 Million

Reuters
·
09 May

Theravance Biopharma Inc: Reaffirming All Financial Guidance Metrics

THOMSON REUTERS
·
09 May